Premium medical cannabis producer, Tilray has recently involved itself in a clinical trial which is set to test the effects of cannabis on treating breast cancer reports Clinical Trials Arena. As per the claims made, the study will be the first ever human testing of its kind, that looks at patients suffering from taxane-induced peripheral neuropathy (TIPN).
Taxane-derived agents are popularly found in chemotherapy drugs used for treating cancer patients. Unfortunately, peripheral neuropathy is deemed one of its adverse effects, which often times is irreversible. In fact, this issue is common across women patients, with at least 67 percent of all cancer patients affected by it. Hence, the need to find a solution for what’s currently used as a solution itself.
The Vice President of Tilray’s Global Patient Research and Access, Philippe Lucas has since shared that Tilray is focused on advancing itself within cannabis research, adding that the firm wishes to contribute to the overall understanding of cannabis benefits.
As for the study, which is expected to last eight weeks, it will be led by Columbia University Irving Medical Center’s psych professor, Diana Martinez and neurobiology professor, Margaret Haney. The method used here is simply dividing the sample into two groups, one receiving a product containing a combination of CBD and THC, while the other will be given a placebo. Haney has since expressed enthusiasm in being part of the cannabis research, noting that:
“There is exciting preclinical evidence showing that THC and CBD significantly reduce TIPN, and our study will be the first to test this in a well-powered clinical trial.”